Cargando…
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/ https://www.ncbi.nlm.nih.gov/pubmed/28154279 |
_version_ | 1782514232710922240 |
---|---|
author | Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo |
author_facet | Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo |
author_sort | Iwaku, Kenji |
collection | PubMed |
description | The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes. |
format | Online Article Text |
id | pubmed-5348459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-53484592017-03-24 Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo Intern Med Case Report The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes. The Japanese Society of Internal Medicine 2017-02-01 /pmc/articles/PMC5348459/ /pubmed/28154279 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title_full | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title_fullStr | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title_full_unstemmed | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title_short | Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine |
title_sort | acute-onset type 1 diabetes that developed during the administration of olanzapine |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/ https://www.ncbi.nlm.nih.gov/pubmed/28154279 |
work_keys_str_mv | AT iwakukenji acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine AT otukafumiko acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine AT taniyamamatsuo acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine |